GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of intent-to-treat vs per-protocol explains half the arguments on this site — 18 comments in the full submission. View in context.
233
c/trialwatch·submitted 13 days ago by u/anders_vermeulen

intent-to-treat vs per-protocol explains half the arguments on this site

Readoutbranch of 6 comments

Trying to settle this properly because the thread from last year went in circles. The claim: STEP matters. The counter-claim: it is measurement error. Both sides have been asserting it confidently for about 8 months without either producing anything. What would actually settle it is 9 people measuring the same thing…

Read the full submission and all 18 comments →

This branch

6 comments, started 11 days ago
u/yara_mensah28 points·11 days ago

the discontinuation arms are the interesting part, not the SURPASS endpoints

replysharereportpermalink
u/prior_auth_painappeals0 points·11 days ago

You have restated the marketing copy. What is the actual substance here.

replysharereportpermalink
u/laila_almeida1 point·10 days ago

This is the "correlation is mechanism" thing again. You changed three variables at once.

replysharereportpermalink
u/cloudy_vial_carol1 point·11 days ago

event rates are more informative than hazard ratios alone

replysharereportpermalink
u/anders_vermeulenOP-29 points·10 days ago

dropout handling matters, especially on GI-heavy populations

replysharereportpermalink
[deleted]11 points·11 days ago

[deleted]

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →